The Cigna Group (CI) Stock Price & How to Invest

The Cigna Group is a large US health-services company built around two main engines. Its Evernorth health-services arm includes Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, plus specialty pharmacy, care services, and pharmacy-related businesses; this is now the larger revenue and growth driver. Its Cigna Healthcare arm sells commercial health insurance, primarily to employers and individuals, along with international and supplemental coverage. Cigna makes money by collecting insurance premiums and managing medical costs, and by earning fees and spreads on managing drug benefits, negotiating with manufacturers, and dispensing specialty medications at scale. After exiting most of its Medicare businesses, Cigna is increasingly weighted toward commercial insurance and pharmacy services rather than government programs. It is headquartered in Bloomfield, Connecticut, and serves employers, health plans, government entities, and individuals.

Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. Health insurers also face rising medical-cost trends and utilization, which can squeeze margins. Concentration in a few large clients (including a major contract with Centene-related and Cigna's own plans) and reliance on retaining big PBM clients add risk. Drug-pricing reform, GLP-1 cost dynamics, litigation, and competitive pressure from vertically integrated rivals like UnitedHealth and CVS all weigh on the outlook. The stock often trades at a low multiple reflecting these regulatory overhangs.

24 analysts publish price targets on CI, averaging $340.92 against a $298.06 price as of July 2026, or +14.4%. The published targets run from $290.00 to $400.00, a moderate spread, and the ratings split 20 buy, 4 hold, 0 sell. Over the last six months there have been 10 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on The Cigna Group. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Evernorth and pharmacy services scale. Evernorth, anchored by Express Scripts, is Cigna's growth engine. The most optimistic published target, $400.00, assumes this works close to its best case.

The case against. Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. The most pessimistic target, $290.00, is roughly what CI is worth if this bites instead.

Read the full bull and bear case on CI, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see The Cigna Group's investor relations page or your broker.

• Revenue (TTM): ~$250 billion (inflated by pharmacy pass-through revenue)
• Operating margin: thin on a revenue basis (PBM pass-through), measured better on adjusted EPS
• Adjusted EPS: double-digit growth targeted over time
• Dividend yield: ~2%
• P/E (TTM): low, often ~12-15x on forward earnings
• Free cash flow: strong, funding large buybacks
• Segments: Evernorth (pharmacy/health services) and Cigna Healthcare (insurance)

Cigna trades at a low earnings multiple relative to the broad market, a discount that reflects PBM regulatory risk and the optically huge but low-margin pharmacy pass-through revenue. The bull case leans on steady adjusted EPS growth, heavy buybacks, and Evernorth's scale; the discounted valuation is the market pricing in policy and drug-pricing uncertainty.

Other names that sit close to CI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The Cigna Group (CI) is a PBM-and-insurance combination whose growth leans on Evernorth's pharmacy scale and the rising tide of specialty and GLP-1 drug spend. In a portfolio it behaves as a defensive, value-multiple healthcare holding with heavy buybacks, discounted by the market for PBM regulatory and drug-pricing-reform risk rather than for weak cash generation.

Whether CI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CI a buy or a sell?, and where the stock could go from here in the CI stock forecast.

For income investors, whether CI pays a dividend and how the payout looks is covered in does CI pay a dividend? And to weigh CI against a peer, read the full side-by-side comparisons: CI vs UNH and CI vs ELV.